Ian Lai

478 total citations
9 papers, 260 citations indexed

About

Ian Lai is a scholar working on Molecular Biology, Cancer Research and Immunology. According to data from OpenAlex, Ian Lai has authored 9 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Immunology. Recurrent topics in Ian Lai's work include PI3K/AKT/mTOR signaling in cancer (3 papers), Immunotherapy and Immune Responses (2 papers) and Immune cells in cancer (2 papers). Ian Lai is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (3 papers), Immunotherapy and Immune Responses (2 papers) and Immune cells in cancer (2 papers). Ian Lai collaborates with scholars based in United States, Denmark and India. Ian Lai's co-authors include Dean W. Felsher, Renumathy Dhanasekaran, Virginie Baylot, Adriane Mosley, Meital Gabay, Srividya Swaminathan, Nia Adeniji, Sibu Kuruvilla, Andrew J. Gentles and Sonya Zabludoff and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and eLife.

In The Last Decade

Ian Lai

8 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian Lai United States	6	165	85	84	73	26	9	260
Shuanglin Han Australia	6	180 1.1×	72 0.8×	66 0.8×	141 1.9×	28 1.1×	7	293
Seung-Pil Shin South Korea	10	198 1.2×	72 0.8×	113 1.3×	79 1.1×	10 0.4×	18	333
Brian J. Mog United States	6	124 0.8×	132 1.6×	169 2.0×	49 0.7×	41 1.6×	10	291
Yunbo He China	4	105 0.6×	152 1.8×	108 1.3×	51 0.7×	14 0.5×	9	284
José Javier United States	4	125 0.8×	79 0.9×	68 0.8×	30 0.4×	25 1.0×	8	289
Guojie Zhong United States	4	148 0.9×	92 1.1×	61 0.7×	28 0.4×	39 1.5×	8	235
Zhewei Tang China	6	128 0.8×	87 1.0×	93 1.1×	25 0.3×	16 0.6×	8	305
Chérine Abou Fayçal France	11	177 1.1×	69 0.8×	72 0.9×	73 1.0×	9 0.3×	14	301
Mitra Ghasemi Chaleshtari Canada	5	123 0.7×	75 0.9×	92 1.1×	64 0.9×	36 1.4×	5	225
Norbert Wiedemann Switzerland	9	252 1.5×	63 0.7×	118 1.4×	56 0.8×	9 0.3×	15	347

Countries citing papers authored by Ian Lai

Since Specialization

Citations

This map shows the geographic impact of Ian Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Lai more than expected).

Fields of papers citing papers by Ian Lai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Lai. The network helps show where Ian Lai may publish in the future.

Co-authorship network of co-authors of Ian Lai

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Lai. A scholar is included among the top collaborators of Ian Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Lai. Ian Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Mahauad‐Fernandez, Wadie D., Yu Chi Yang, Ian Lai, et al.. (2025). Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers. Cell chemical biology. 32(8). 994–1012.e11.

Mahauad‐Fernandez, Wadie D., Yu Chi Yang, Ian Lai, et al.. (2023). Abstract LB015: Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression. Cancer Research. 83(8_Supplement). LB015–LB015. 1 indexed citations

Dhanasekaran, Renumathy, Aida S. Hansen, L Lemaître, et al.. (2022). MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages. Cancer Research. 83(4). 626–640. 28 indexed citations

Ma, Qing, Liuyi Yang, Karen Tolentino, et al.. (2022). Inducible lncRNA transgenic mice reveal continual role of HOTAIR in promoting breast cancer metastasis. eLife. 11. 31 indexed citations

Wang, Zhichao, Khyatiben V. Pathak, Seema B. Plaisier, et al.. (2021). Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies. SHILAP Revista de lepidopterología. 9(1). 31–31. 6 indexed citations

Mahauad‐Fernandez, Wadie D., Yu Chi Yang, Ian Lai, et al.. (2021). Abstract 1002: A bi-steric mTORC1 inhibitor that selectively reactivates 4EBP1 and induces regression of MYC-driven hepatocellular carcinoma. Cancer Research. 81(13_Supplement). 1002–1002. 1 indexed citations

Dhanasekaran, Renumathy, Virginie Baylot, Sibu Kuruvilla, et al.. (2020). MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. eLife. 9. 46 indexed citations

Lai, Ian, Srividya Swaminathan, Virginie Baylot, et al.. (2018). Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 6(1). 125–125. 109 indexed citations

Dhanasekaran, Renumathy, Virginie Baylot, Ian Lai, et al.. (2017). Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget. 9(5). 5517–5528. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact